New pharmacological approaches for the treatment of alcoholism.

Abstract:

:Pharmacological relapse prevention in alcoholism is a rather new clinical field with few drugs being available. Acamprosate, acting predominantly via glutamatergic pathways, and the opioid receptor antagonist naltrexone, were both shown to be efficient in improving rates for continuous abstinence, and not relapsing to heavy drinking in a number of clinical trials and meta-analyses. There are conflicting data on both drugs, especially for acamprosate, according to some recent US studies. However, overall, the evidence is good. Both drugs are approved in most European countries and the US. Efficacy data for disulfiram are mixed; it is a second-line medication compared with other drugs, and is probably most effective when used in a supervised setting. Recently, anticonvulsants including carbamazepine and topiramate have been discussed as possible anti-craving drugs, but there is still limited evidence for their efficacy. Although there is a significant comorbidity for alcoholism with affective disorder, anxiety and schizophrenia, relatively few controlled clinical trials have been performed in this area. Tricyclics have been found to be more effective than serotonin reuptake inhibitors in improving depressive symptoms in these patients.

authors

Soyka M,Roesner S

doi

10.1517/14656566.7.17.2341

subject

Has Abstract

pub_date

2006-12-01 00:00:00

pages

2341-53

issue

17

eissn

1465-6566

issn

1744-7666

journal_volume

7

pub_type

杂志文章,评审
  • Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

    abstract:INTRODUCTION:Colorectal cancer (CRC) is the third most common cancer in the western world and also in Japan. The key factors in curing CRC are early detection, surgery and adequate adjuvant chemotherapy if needed. AREAS COVERED:Based on the results of following pivotal adjuvant trials, FOLFOX or XELOX are considered s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145665

    authors: Tsuji Y,Sugihara K

    更新日期:2016-01-01 00:00:00

  • Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study.

    abstract:OBJECTIVE:The aim of this study was to assess the effect of aliskiren and amlopidine on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP). RESEARCH DESIGN AND METHODS:After 4-week placebo, 120 outpatients with grade 1 - 2 hypertension were randomized to amlodipine 10 mg or aliskiren 300 mg or t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656566.2011.580276

    authors: Fogari R,Zoppi A,Mugellini A,Maffioli P,Lazzari P,Monti C,Derosa G

    更新日期:2011-06-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • An overview of lefamulin for the treatment of community acquired bacterial pneumonia.

    abstract:INTRODUCTION:Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, including atypical pathogens, that cause community-acquired pneumonia (CAP). AREAS COVERED:This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1714592

    authors: Falcó V,Burgos J,Almirante B

    更新日期:2020-04-01 00:00:00

  • Assessment and management of acute pain in high-risk neonates.

    abstract::Neonates in the neonatal intensive care unit experience hundreds of painful procedures at a time of rapid neurological development. Although the immediate responses to pain may be protective, the potential long-term effects of early and under-treated pain are concerning. As pain assessment is the first step in the pro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.4.475

    authors: Gibbins S,Stevens B,Asztalos E

    更新日期:2003-04-01 00:00:00

  • Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

    abstract:INTRODUCTION:The epidermal growth factor receptor (EGFR) is mutated in 15% of adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered in 8% of adenocarcinomas of the lung. Treatment of EGFR mutant and ALK translocation-positive tumors in NSCLC with tyrosine kinase inhibitors (TKI) resu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.971013

    authors: Somasundaram A,Socinski MA,Burns TF

    更新日期:2014-12-01 00:00:00

  • Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?

    abstract::Glycosuria is being increasingly recognised as not only a symptom but also as a novel therapeutic approach in the management of type 2 diabetes mellitus (T2DM). This is accomplished through sodium glucose co-transporter 2 (SGLT2) inhibitors. Consequently, the safety and efficacy of these new agents have been thoroughl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2015.994505

    authors: Pafili K,Papanas N

    更新日期:2015-03-01 00:00:00

  • Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

    abstract:INTRODUCTION:PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-medi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1737010

    authors: Kienle DL,Stilgenbauer S

    更新日期:2020-06-01 00:00:00

  • Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient.

    abstract::Symptomatic and asymptomatic peripheral arterial occlusive disease (PAD) is indicative of widespread atherosclerosis. The major threat is from cardiovascular ischaemic events; thus, an important therapeutic goal is to modify atherosclerotic risk factors. Data from several large drug trials indicate that patients with ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.13.2181

    authors: Baumgartner I

    更新日期:2005-10-01 00:00:00

  • High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.

    abstract:BACKGROUND:There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent lesion formation, decrease the rate and severity of relapses and delay the resulting disability by reducing levels of inflammation. OBJECTIVE:The aim of this review was to assess the treatment o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560802677882

    authors: Hartung HP

    更新日期:2009-02-01 00:00:00

  • Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome.

    abstract::Shock associated with systemic inflammatory response syndrome (SIRS) is a form of distributive shock affecting over 200,000 patients per year in the US that results in 50% mortality. The role of NO in a variety of shock states has been extensively studied and has been shown to be the primary effector in endotoxin lipo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.1.19

    authors: De Angelo J

    更新日期:1999-11-01 00:00:00

  • Alprazolam extended-release in panic disorder.

    abstract::Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels. The anti-panic efficacy of alpra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1517/14656566.5.7.1599

    authors: Rickels K

    更新日期:2004-07-01 00:00:00

  • Safinamide in the treatment of Parkinson's disease.

    abstract:IMPORTANCE OF THE FIELD:Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.511612

    authors: Schapira AH

    更新日期:2010-09-01 00:00:00

  • Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?

    abstract::Bupropion, a noradrenaline and dopamine re-uptake inhibitor, has long been indicated for the treatment of depression. Recent studies have demonstrated additional benefits in depression, including: prevention of the recurrence of seasonal affective disorder in depressive subtypes with decreased energy, pleasure and int...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.4.457

    authors: Clayton AH

    更新日期:2007-03-01 00:00:00

  • Pharmacotherapy of retinal disease with visual cycle modulators.

    abstract:INTRODUCTION:Pharmacotherapy with visual cycle modulators (VCMs) is under investigation for retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related macular degeneration (AMD), all blinding diseases that lack effective treatment options. AREAS COVERED:...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1448060

    authors: Hussain RM,Gregori NZ,Ciulla TA,Lam BL

    更新日期:2018-04-01 00:00:00

  • Lipid pharmacotherapy for treatment of atherosclerosis.

    abstract:INTRODUCTION:For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.904287

    authors: Nicholls SJ,Pisaniello AD,Kataoka Y,Puri R

    更新日期:2014-06-01 00:00:00

  • Synthetic pharmacotherapy for lupus nephritis.

    abstract:INTRODUCTION:Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aime...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1276563

    authors: Moroni G,Ponticelli C

    更新日期:2017-02-01 00:00:00

  • Sustained release oral fampridine in the treatment of multiple sclerosis.

    abstract:BACKGROUND:Fampridine-SR is under submission as the first drug to be FDA approved with an indication specifically for multiple sclerosis symptoms. Compounded forms of the active agent of Fampridine-SR (4-aminopyridine) have been used in clinical practice for many years. Clinical trials have now been completed that demo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903075994

    authors: Kachuck NJ

    更新日期:2009-08-01 00:00:00

  • Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

    abstract:INTRODUCTION:Silodosin is a new uroselective alpha-blocker with high pharmacological selectivity for the (1A) adrenoceptor. It is an effective and well-tolerated treatment in men with lower urinary tract symptoms (LUTS), due to presumed bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The eff...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.714368

    authors: Osman NI,Chapple CR,Cruz F,Desgrandchamps F,Llorente C,Montorsi F

    更新日期:2012-10-01 00:00:00

  • Emerging antiretroviral drugs.

    abstract:INTRODUCTION:The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and hi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.863277

    authors: Fernández-Montero JV,Vispo E,Soriano V

    更新日期:2014-02-01 00:00:00

  • The role of aspirin in cardiovascular diseases--forgotten benefits?

    abstract::The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention. Aspirin should be ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.1.109

    authors: Williams A,Hennekens CH

    更新日期:2004-01-01 00:00:00

  • Cost-effectiveness of pharmacotherapy for autoimmune hepatitis.

    abstract::In > 80% of patients with autoimmune hepatitis, steroid therapy alone or in combination with azathioprine results in disease remission. Treatment response results in reversal of fibrosis and excellent long-term survival in many patients, whereas untreated patients may expect a 10-year survival of < 30%. The use of aza...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.2.145

    authors: Heneghan MA,Al-Chalabi T,McFarlane IG

    更新日期:2006-02-01 00:00:00

  • Emerging therapies for ionizing radiation-associated skin field carcinogenesis.

    abstract:BACKGROUND:Radiodermatitis in its acute and chronic presentations represents a set of specific adverse effects resulting from ionizing radiations. Skin-field cancerization is another condition associated to or independent of clinically recognizable radiodermatitis. This condition leads to the risk of later occurrence o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902754060

    authors: Piérard GE,Piérard-Franchimont C,Paquet P,Quatresooz P

    更新日期:2009-04-01 00:00:00

  • Combination strategies for pain management.

    abstract::At least two factors relating to pain management using oral analgesics suggest that combination strategies merit consideration: many pains arise from more than one physiological cause and current analgesics have adverse effect profiles that might be reduced by combination with another agent in smaller doses or with le...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.10.1697

    authors: Raffa RB,Clark-Vetri R,Tallarida RJ,Wertheimer AI

    更新日期:2003-10-01 00:00:00

  • Etravirine for the treatment of HIV/AIDS.

    abstract:INTRODUCTION:Etravirine (TMC125) is an orally administered second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved in treatment-experienced patients as addition to an optimized background therapy (OBT). AREAS COVERED:A Medline search was conducted of Phase II - IV clinical trials, as ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.787411

    authors: Schrijvers R

    更新日期:2013-06-01 00:00:00

  • Clinical review of Clostridium difficile infection: an update on treatment and prevention.

    abstract:INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524872

    authors: Daniels LM,Kufel WD

    更新日期:2018-11-01 00:00:00

  • Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult women.

    abstract::Urinary tract infections (UTIs) are among the most commonly encountered bacterial infections. Acute uncomplicated UTIs in adults include episodes of cystitis and pyelonephritis. The main uropathogens causing uncomplicated UTIs have, in the past, been fairly predictable and they have generally been susceptible to sever...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.8.1227

    authors: Garrison J,Hooton TM

    更新日期:2001-08-01 00:00:00

  • The pharmacogenetics of analgesia.

    abstract::Genomic variations influencing response to pharmacotherapy of pain are under investigation. Candidate genes such as (opioid)-receptors, transporters and other molecules important for pharmacotherapy are discussed. Drug metabolising enzymes represent a further major target of ongoing research in order to identify assoc...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.14.2235

    authors: Stamer UM,Stüber F

    更新日期:2007-10-01 00:00:00

  • Everolimus: preventing organ rejection in adult kidney transplant recipients.

    abstract:INTRODUCTION:Kidney transplantation is the treatment of choice for patients with end-stage renal failure, and their survival after transplantation is gradually improving. Everolimus (EVL) is a mammalian target of rapamycin inhibitor, providing a safe and effective immunosuppressive regime after kidney transplantation. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.662955

    authors: Dantal J

    更新日期:2012-04-01 00:00:00

  • Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.

    abstract:INTRODUCTION:In the 40-50% of advanced melanoma patients with tumors harboring BRAF V600E and V600 K mutations, BRAF inhibitors such as dabrafenib are a highly effective treatment. However, most patients develop resistance after several months on treatment. The addition of a MEK inhibitor, such as trametinib, to BRAF i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1168805

    authors: Spain L,Julve M,Larkin J

    更新日期:2016-01-01 00:00:00